Mitchell V. Mathis, MD
- 4Articles
- 15.9KReads
- 2014–2018Active
- 23Collaborators
- 96Citations
About
Mitchell V. Mathis, MD, has published extensively on regulatory perspectives related to psychopharmacology, focusing on the US Food and Drug Administration's evaluation of new psychiatric medications. His work addresses topics including major depressive disorder, neurology, and clinical trial methodologies, particularly concerning antidepressants and antipsychotics such as aripiprazole, pimavanserin, and vortioxetine. Mathis has contributed to discussions on regulatory and scientific challenges in assessing sexual dysfunction in antidepressant trials.
Publications
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
